Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294870 | 0.98 | NPC1 (0.39) | HDAC1HDAC6CNR2NPC1PLA2G2A | |
| SCHEMBL16880097 | 0.89 | SCARB1 (0.43) | HDAC1HDAC6CNR2PLA2G2ACNR1 | |
| SCHEMBL16880336 | 0.89 | HDAC6 (0.50) | HDAC1HDAC6 | |
| SCHEMBL16879860 | 0.88 | HDAC6 (0.50) | HDAC1HDAC6 | |
| SCHEMBL16879926 | 0.88 | HRH1 (0.42) | HDAC1HDAC6CNR2PLA2G2ACNR1 | |
| SCHEMBL16879875 | 0.84 | HDAC6 (0.52) | HDAC1HDAC6 | |
| SCHEMBL16880198 | 0.83 | PTGER4 (0.44) | NPC1CNR1KDM4E | |
| SCHEMBL18294890 | 0.83 | HDAC1 (0.39) | HDAC1HDAC6NPC1PLA2G2APLA2G10 | |
| SCHEMBL18294869 | 0.81 | ESR1 (0.38) | HDAC1HDAC6PLA2G2APLA2G10CNR1 | |
| SCHEMBL18294882 | 0.81 | GAA (0.40) | HDAC1HDAC6NPC1PLA2G2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC2, HDAC1, HDAC3 | HDAC1 2/4885HDAC6 4/4885CNR2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.